Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06356129 · ClinicalTrials.gov registry record · Phase 3

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

A Phase 3 study of Large B-cell Lymphoma, sponsored by Celgene.

Active
Registry status
Phase 3
Development phase
850
Enrollment target
20
Study locations

NCT06356129 is a Phase 3 study of Large B-cell Lymphoma that is active but no longer recruiting, run by Celgene. The registered enrollment target is 850 participants, above the 129-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (559% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06356129, a Phase 3 study of Large B-cell Lymphoma, is active but no longer recruiting, sponsored by Celgene.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
850 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).

Conditions Studied

Large B-cell Lymphoma

Interventions

  • DRUG Cyclophosphamide
  • DRUG Placebo
  • DRUG Doxorubicin
  • DRUG Rituximab
  • DRUG Golcadomide

Study Locations (20)

Florida

  • Local Institution - 0497 - Fort Myers
  • Local Institution - 0287 - Jacksonville
  • Local Institution - 0415 - Margate
  • Local Institution - 0045 - Miami Beach
  • Local Institution - 0012 - Pensacola
  • Local Institution - 0502 - St. Petersburg
  • Local Institution - 0414 - Tampa
  • Local Institution - 0192 - West Palm Beach
  • Local Institution - 0485 - Weston

Georgia

  • Local Institution - 0515 - Atlanta
  • Local Institution - 0303 - Atlanta

Illinois

  • Local Institution - 0182 - Chicago
  • Local Institution - 0048 - Skokie

Alabama

  • Local Institution - 0014 - Mobile

Alaska

  • Local Institution - 0477 - Anchorage

Arizona

  • Local Institution - 0452 - Phoenix

California

  • Local Institution - 0342 - San Francisco

Iowa

  • Local Institution - 0461 - Waukee

Trial Details

FieldValue
Enrollment Target 850 participants
Start Date 2024-06-19
Est. Completion 2029-11-20
Phase Phase 3

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06356129

The ClinicalTrials.gov registry entry for NCT06356129 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 129-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (559% higher). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT06356129 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT06356129 about?

NCT06356129 is a clinical study titled "Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma". The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk l...

What is the current status of trial NCT06356129?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 850 participants. The study started on 2024-06-19. Estimated completion is 2029-11-20.

What conditions does trial NCT06356129 study?

This clinical trial studies the following conditions: Large B-cell Lymphoma.

What interventions are being tested in trial NCT06356129?

The interventions under investigation include: Cyclophosphamide (DRUG), Placebo (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Golcadomide (DRUG).

Who is sponsoring clinical trial NCT06356129?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06356129 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Large B-cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Large B-cell Lymphoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.